who concluded that she likely did not have Parkinson disease but could be experiencing extrapyramidal symptoms secondary to olanzapine use. Carbidopa–levodopa was discontinued at this time.

With nearly 30 years of clinical and real-world use, olanzapine is one of the most commonly prescribed second-generation oral antipsychotics for the treatment of schizophrenia globally ...

For healthcare providers and patients, PDSS remains a barrier to the widespread use of olanzapine LAI. The requirement for close post-injection monitoring limits the convenience and flexibility of ...

Implementation of a policy that increased pharmacist surveillance and regulation of the use of intramuscular olanzapine reduced the potential for coadministration of the agent with parenteral ...

Olanzapine extended-release 210mg/vial ... Elderly with dementia-related psychosis (not approved use); increased risk of death or cerebrovascular events (eg, stroke, TIA). Cardio- or ...

Olanzapine 5mg, 10mg ... Elderly with dementia-related psychosis (not approved use); increased risk of death or cerebrovascular events (eg, stroke, TIA). Discontinue if neuroleptic malignant ...

subcutaneous long-acting injection of the atypical antipsychotic olanzapine for the treatment of schizophrenia. This is the second drug within the partnership with Teva that uses Medincell’s co ...